Johnson & Johnson is getting ready to release a new drug to treat Hepatitis C. Early clinical trials meet FDA safety profile standards and should be approved after further studies. The new drug, simeprevir, was used in trials to treat patients who did not respond to previous interferon-based therapy or who had not received prior treatment. This new drug would be the first oral treatment that would allow patients to forego injection treatment. The current interferon injection treatments are difficult to tolerate and do not work for all patients. Other pharmaceutical companies are also working on trials of new oral drugs to treat Hepatitis C.